Sichuan Province Shuzhong Pharmacy Co., Ltd.

Primary objective: To investigate the pharmacokinetic characteristics of a single oral dose of the test formulation dapoxetine hydrochloride tablets (60 mg, manufactured by Sichuan Yike Pharmaceutical Co., Ltd.) and the reference formulation dapoxetine hydrochloride tablets (Priligy®, 60 mg; manufactured by Menarini-Von Heyden GmbH) in healthy male participants under fasting and postprandial conditions, and to evaluate the bioequivalence of the two formulations under fasting and postprandial conditions. Secondary objective: To investigate the safety of the test formulation dapoxetine hydrochloride tablets (60 mg) and the reference formulation dapoxetine hydrochloride tablets (Priligy®) (60 mg) in healthy male participants.

Primary Objective: To investigate the bioequivalence of Sildenafil Citrate Tablets (T, 100 mg) from Sichuan Yike Pharmaceutical Co., Ltd. and Sildenafil Citrate Tablets (R, trade name: Viagra®, 100 mg) from Pfizer Inc. in healthy male subjects using the test formulation and the reference formulation, according to relevant bioequivalence testing regulations. Secondary Objective: To observe the safety of Sildenafil Citrate Tablets in healthy male subjects.

Primary Objective: To evaluate the in vivo pharmacokinetic characteristics of bromhexine hydrochloride tablets (strength: 8 mg) produced by Sichuan Yike Pharmaceutical Co., Ltd. and the reference preparation bromhexine hydrochloride tablets (strength: 8 mg; trade name: Bisolvon®) in healthy Chinese volunteers after a single oral dose in the fasting and fed state, and to assess the bioequivalence of the two formulations. Secondary Objective: To evaluate the safety of a single oral dose of bromhexine hydrochloride tablets (strength: 8 mg) in healthy Chinese volunteers.